Copyright
©The Author(s) 2023.
World J Hepatol. Aug 27, 2023; 15(8): 939-953
Published online Aug 27, 2023. doi: 10.4254/wjh.v15.i8.939
Published online Aug 27, 2023. doi: 10.4254/wjh.v15.i8.939
Inclusion criteria | Exclusion criteria |
Evidence of positive tumor cells or cells strongly suspicious for CCA on biopsy | Evidence of extra hepatic disease or lymph node enlargement |
Malignant appearing stricture on radiograph and 1 of the following criteria (a or b or c) | Previous malignancy excluding skin or cervical cancer within 5 yr before diagnosis of cholangiocarcinoma |
a. Ca 19-19 > 100 U/mL in the absence of acute bacterial cholangitis | History of abdominal radiotherapy |
b. Polysomy on fluorescence in-situ hybridization | Uncontrolled infection before treatment |
c. Hilar mass < 3 cm in radial diameter on cross-sectional imaging | Prior attempt of surgical tumors reaction and subsequent violation of tumor plane |
- | Any medical condition precluding transplantation |
- | Any transperitoneal biopsy including percutaneous and/or endoscopic ultrasonographic-guided fine needle aspiration |
- Citation: Shah YR, Nombera-Aznaran N, Guevara-Lazo D, Calderon-Martinez E, Tiwari A, Kanumilli S, Shah P, Pinnam BSM, Ali H, Dahiya DS. Liver transplant in primary sclerosing cholangitis: Current trends and future directions. World J Hepatol 2023; 15(8): 939-953
- URL: https://www.wjgnet.com/1948-5182/full/v15/i8/939.htm
- DOI: https://dx.doi.org/10.4254/wjh.v15.i8.939